ZYJ-34c

• Description:

  ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC50s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model[1].

• UNSPSC:

  12352005

• Target:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/zyj-34c.html

• Smiles:

  CC(C)(C)CC(N[C@@H]([C@@H](C)CC)C(N1[C@@H](CC2=CC=C(OCC(NO)=O)C=C2C1)C(NC3=CC=C(C=C3)OC)=O)=O)=O

• Molecular Formula:

  C31H42N4O7

• Molecular Weight:

  582.69

• References & Citations:

  [1]Yingjie Zhang, et al. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem. 2011 Aug 11;54 (15) :5532-9.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC6; HDAC8

• CAS Number:

  [1314556-93-8]